Cancer Genetics India Partners with CSIR-Centre fo

• Scientists at CSIR-CCMB conduct groundbreaking multi-disciplinary research in the area of modern biology and aim to promote collaborative research using advanced technologies that enable omics-based research.             

HYDERABAD, India, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) (“CGI” or “The Company”), a leader in precision diagnostics for oncology, announced today that Cancer Genetics India (CG India) and CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) have jointly organized the 2nd Annual NGS Conference taking place from 22nd to 24th of February 2017 in Hyderabad, India. The conference will bring together eminent scientists from several government research institutions that conduct cutting edge biological research using NGS technology and bioinformatics. The objective of the conference is to provide recent updates and discuss the impact of diverse yet relevant applications of NGS and bioinformatics on key research areas such as agri-genomics, onco-genomics, microbiology, and human genetics.

The opening day of the conference coincided with the 89th birthday of Dr. P. M. Bhargava, the founder of CSIR-CCMB. On this occasion, CSIR-CCMB had organized a “Founder’s Day Celebration,” which was a great opportunity to interact with one of India’s most celebrated scientists. “We are delighted to partner with CG India to welcome all speakers and participants to hear from Dr. T Ramasamy, the distinguished speaker on this occasion,” said Dr. Rakesh Mishra, Director, CSIR-CCMB. “We are looking forward to a great conference that will promote cross-disciplinary research collaborations across India.”

Comprehensive genomics services are central to CG India’s business model and are at the forefront of several scientific investigations carried out by scientists at CSIR-CCMB. Together, the two organizations believe that this platform will foster productive research collaborations that improve human health. CG India’s state-of-the-art facility, extensive expertise in developing customized NGS protocols, experience with routine assays, and comprehensive capabilities in analyzing NGS data will greatly support such research collaborations.

“We are excited about this event and look forward to support and fulfill the scientific demands of leading scientists in the area of genomics, by providing high quality NGS and bioinformatics services,” said Mr. Panna Sharma, CEO and President of CGI. “As we help molecular oncologists gain novel insights in the molecular epidemiology of certain cancers in the Indian context, we look forward to developing research and clinical collaborations with leading cancer research centers and academic institutions.”

The conference will highlight work in the area of genomics- driven findings in oncology to promote awareness about cancer related discoveries and explore how they may translate into personalized oncology applications. For more information, please visit http://cgiindia.in/NGSSymposium/ .

ABOUT CANCER GENETICS Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at: Internet:  www.cancergenetics.com Twitter:  @Cancer_Genetics Facebook:  Cancer Genetics, Inc. or CG India

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Contact: Panna Sharma CEO & President Cancer Genetics, Inc. Tel: 201-528-9200 Email: panna.sharma@cgix.com